Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2008

Schultheis Anne M, Lurje Georg, Rhodes Katrin E, Zhang Wu, Yang Dongyun, Garcia Agustin A, Morgan Robert, Gandara David, Scudder Sidney, Oza Amit, Hirte Hal, Fleming Gini, Roman Lynda, Lenz Heinz-Josef

Abstract excerpt

PURPOSE: This study was designed to evaluate the associations between angiogenesis gene polymorphisms and clinical outcome in ovarian cancer patients treated with low-dose cyclophosphamide and bevacizumab. EXPERIMENTAL DESIGN: Seventy recurrent/metastatic epithelial ovarian cancer patients were e...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Bevacizumab

Share to Cyclophosphamide

Share to Disease-Free Survival

Share to Kaplan-Meier Estimate

Share to Pilot Projects

Source

Open in PubMed Open full text

Identifiers

PMID: 19010874
DOI: 10.1158/1078-0432.CCR-08-0351
PMCID: PMC2586993

Genes

CXCR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19010874-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.PMID 19010874Read ↗

Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis.Semantic proximity Read ↗

Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival.Semantic proximity Read ↗

Impact of Angiogenesis- and Hypoxia-Associated Polymorphisms on Tumor Recurrence in Patients with Hepatocellular Carcinoma Undergoing Surgical ResectionSemantic proximity Read ↗

Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with first-line cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancer.Semantic proximity Read ↗

VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients.Semantic proximity Read ↗

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.Semantic proximity Read ↗

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.Semantic proximity Read ↗

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.Semantic proximity Read ↗

Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancerSemantic proximity Read ↗

Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome.Semantic proximity Read ↗

IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.